The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of immune exhaustion across the evolution of oligometastatic clear cell renal cell carcinoma using spatially resolved tissue immune profiling: Secondary analysis of a prospective trial.
 
Kieko Hara
No Relationships to Disclose
 
Guillermo E Corredor-Alonso
Consulting or Advisory Role - AstraZeneca
 
Alejandra G Serrano
No Relationships to Disclose
 
Sharia D Hernandez
No Relationships to Disclose
 
Wei Lu
No Relationships to Disclose
 
Amishi Yogesh Shah
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Exelixis; Pfizer/EMD Serono
Research Funding - 4D Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst)
 
Eric Jonasch
Consulting or Advisory Role - aravive; Aveo; Calithera Biosciences; Eisai; Exelixis; Merck; NiKang Therapeutics; Novartis; Pfizer; Takeda
Research Funding - Arrowhead Pharmaceuticals (Inst); Merck; NiKang Therapeutics; Novartis
Travel, Accommodations, Expenses - Pfizer
 
Jose A. Karam
Stock and Other Ownership Interests - Medtek; ROM Tech
Consulting or Advisory Role - Johnson & Johnson/Janssen; Merck; Pfizer
Research Funding - Elypta (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Surena F. Matin
Consulting or Advisory Role - Johnson & Johnson; Merck
Research Funding - Helsinn Therapeutics/QED Therapeutics
Other Relationship - Elsevier
 
Nizar M. Tannir
Stock and Other Ownership Interests - Amgen; Arcturus Therapeutics; Arcus Biosciences; BioCryst; Corvus Pharmaceuticals; First Trust Amex Biotech (FBT); Johnson & Johnson/Janssen; Merck; Nuvation Bio; Revolution Medicines; Surface Oncology; Vanguard Health Care; Xencor
Honoraria - AstraZeneca/Merck; Bristol-Myers Squibb; Eisai; Exelixis; Intellisphere; Merck Sharp & Dohme; Neoleukin Therapeutics; Oncorena
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Merck Sharp & Dohme; Nektar; Oncorena
Research Funding - Arrowhead Pharmaceuticals (Inst); Bristol Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Nektar (Inst); Novartis (Inst)
 
Pavlos Msaouel
Honoraria - Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Axiom Healthcare Strategies
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Kanishka Sircar
No Relationships to Disclose
 
Luisa Maren Solis
No Relationships to Disclose
 
Chad Tang
Consulting or Advisory Role - Bayer; Diffusion Pharmaceuticals; Reflexion Medical
Patents, Royalties, Other Intellectual Property - I have a patent on the utilization of a monoclonal antibody and we license this for use. We receive royalties <$1000 per year on this license.
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - Wolters Kluwer